May 17, 2021 -- Soteria Biotherapeutics has closed $42 million in financing to launch as an immuno-oncology company focused on developing next-generation switchable, bispecific T-cell engagers to treat solid tumor cancers.
The company has developed T-Lite T-cell engagers that are selectively switched on through oral administration of a small-molecule activator to modulate potent T-cell activity by controlling the timing, duration, and level of bispecific complex formation. The switchable activity enables precise on/off control over the timing and magnitude of T-cell redirection and cytotoxic activity, according to the company.
The new funding will support the further advancement of the T-Lite technology platform and building of a pipeline of T-Lite candidates in validated cancer targets.
The series A financing was led by Roche Venture Fund and 5AM Ventures with participation from M Ventures, Novartis Venture Fund and Alexandria Venture Investments.
Copyright © 2021 scienceboard.net